Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 454 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Scientists find cells in centre of tumours are most likely to... May 18, 2021 How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment April 12, 2022 A Pet Pug Helped Two Sisters Realize They Both Had Breast... October 16, 2020 The Growths On This Woman’s Lips Are A Sign That She... April 17, 2020 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Rucaparib EMA Recommends Granting a Marketing Authorisation for Ivosidenib Research shows one size doesn’t fit all for cervical screening in... Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial...
